Immunocore表示，新数据证明Kimmtrak对色素瘤的有效性

2024-06-01 23:38

New data from phase 2 and phase 3 trials showed that patients treated with Immunocore's (NASDAQ:IMCR) uveal melanoma therapy Kimmtrak (tebentafusp) who had stable disease and a confirmed tumor reduction had a similar clinical outcome to those with a partial response.
In the phase 2 trial, clinical outcomes in the 26 patients who received Kimmtrak with stable disease were similar to those seen in six partial response patients, such as durable duration of tumor reduction or response, ctDNA molecular response, and overall survival.
In the phase 3 trial, KIMMTRAK-treated patients with stable disease and with any confirmed tumor reduction had durability of tumor reduction of 11 months, the same as the durability of response for patients with partial response or complete response.

More on Immunocore